News

Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday.
In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.
This discovery could make treatment for an eye disease affecting millions with diabetes more accessible and affordable.
The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...
The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for ...
The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to HIV-prevention infrastructure in the U.S.